Antitumor Effects of Cisplatin Combined with Tecemotide Immunotherapy in a Human MUC1 Transgenic Lung Cancer Mouse Model

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer immunology research

• Publication date

  2014-03-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/2326-6066.CIR-13-0205PMID 24894093
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

  2014influential reference
• Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8+ T cells

  2014cited by this paper
• START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer.

  2013cited by this paper
• Immunogenic cell death in cancer therapy.

  2013cited by this paper
• Antitumor effects of L-BLP25 Antigen-Specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model

  2013cited by this paper
• Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy

  2013cited by this paper
• IFN-γ mediates the antitumor effects of radiation therapy in a murine colon tumor.

  2013cited by this paper
• Effects of conventional therapeutic interventions on the number and function of regulatory T cells

  2013cited by this paper
• Non-small cell lung cancer.

  2012cited by this paper
• L-BLP25 Vaccine plus Letrozole Induces a TH1 Immune Response and Has Additive Antitumor Activity in MUC1-Expressing Mammary Tumors in Mice

  2012cited by this paper
• Radiation, Inflammation, and Immune Responses in Cancer

  2012cited by this paper
• Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells

  2011cited by this paper
• Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses

  2011cited by this paper
• Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial

  2011influential reference
• IFN{gamma} mediates the antitumor effects of radiation therapy

  2011cited by this paper
• Cisplatin pretreatment enhances anti-tumor activity of cytokine-induced killer cells.

  2011cited by this paper
• Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.

  2010cited by this paper
• Consecutive low doses of cyclophosphamide preferentially target Tregs and potentiate T cell responses induced by DNA PLG microparticle immunization.

  2010cited by this paper
• Lung Cancer: Are we up to the Challenge?

  2010cited by this paper
• Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

  2010cited by this paper
• MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer.

  2009cited by this paper
• MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion.

  2009cited by this paper
• L-BLP25: A Peptide Vaccine Strategy in Non–Small Cell Lung Cancer

  2007cited by this paper
• Effects of cisplatin, alpha-interferon, and 13-cis retinoic acid on the expression of Fas (CD95), intercellular adhesion molecule-1 (ICAM-1), and epidermal growth factor receptor (EGFR) in oral cancer cell lines.

  2007cited by this paper
• Vaccines for lung cancer.

  2006cited by this paper
• Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide.

  2006cited by this paper
• Immune-Modulating Vaccines in Non-small Cell Lung Cancer

  2006influential reference
• Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.

  2005cited by this paper
• Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.

  2005influential reference
• Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response

  2005cited by this paper
• Cisplatin augments cytotoxic T-lymphocyte-mediated antitumor immunity in poorly immunogenic murine lung cancer.

  2003cited by this paper
• MUC1 expression in lung cancer.

  2003cited by this paper
• Cisplatin Induces Fas Expression in Esophageal Cancer Cell Lines and Enhanced Cytotoxicity in Combination with LAK Cells

  2000cited by this paper
• Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways.

  2000cited by this paper
• MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients.

  1998cited by this paper
• Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours

  1997cited by this paper
• Heterogeneity of mucin gene expression in normal and neoplastic tissues.

  1993cited by this paper
• Monoclonal antibodies to epithelial sialomucins recognize epitopes at different cellular sites in adenolymphomas of the parotid gland

  1988cited by this paper
• Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset.

  1987cited by this paper

• Enhancing Cancer Treatment Through Combined Approaches: Photodynamic Therapy in Concert with Other Modalities

  2024cites this paper
• Cytokines and radiation-induced pulmonary injuries

  2018cites this paper
• Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer

  2018cites this paper
• Muc1 knockout potentiates murine lung carcinogenesis involving an epiregulin-mediated EGFR activation feedback loop

  2017cites this paper
• MUC1-Mediated Metabolic Alterations Regulate Response to Radiotherapy in Pancreatic Cancer

  2017cites this paper
• Mucin 1 and poly I:C activates dendritic cells and effectively eradicates pituitary tumors as a prophylactic vaccine.

  2016cites this paper
• Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential

  2016cites this paper
• Immunotherapy for non-small cell lung cancer: current concepts and clinical trials.

  2016cites this paper
• Interleukin 12 shows a better curative effect on lung cancer than paclitaxel and cisplatin doublet chemotherapy

  2016cites this paper
• Assessing the Effects of Concurrent versus Sequential Cisplatin/Radiotherapy on Immune Status in Lung Tumor–Bearing C57BL/6 Mice

  2015cites this paper
• Cisplatin in combination with programmed cell death protein 5 increases antitumor activity in prostate cancer cells by promoting apoptosis.

  2015cites this paper
• Efeito sinérgico entre a terapia fotodinâmica e a cisplatina: uma nova abordagem para o câncer de colo uterino

  2015cites this paper
• Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial.

  2014cites this paper
• Synergistic effect of photodynamic therapy and cisplatin: a novel approach for cervical cancer.

  2014cites this paper
• Tecemotide: An antigen-specific cancer immunotherapy

  2014influential citation